Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.4490 +0.0090 (+2.05%)
Streaming Delayed Price Updated: 9:51 AM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 271,244
Open 0.4448
Bid (Size) 0.4480 (2)
Ask (Size) 0.4550 (262)
Prev. Close 0.4400
Today's Range 0.4400 - 0.4550
52wk Range 0.2649 - 1.160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The "Multi-Bagger" Portfolio Continued To Outperform The S&P 500 Last Week
Our basket of mostly microcap cannabis, psychedelic and plant-based food stocks was extremely oversold in 2022 but we're watching for them to bounce back in 2023. 
Via Talk Markets
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga

Performance

YTD
+48.18%
+48.18%
1 Month
-9.29%
-9.29%
3 Month
-1.32%
-1.32%
6 Month
-37.20%
-37.20%
1 Year
-58.81%
-58.81%

More News

Read More
The 7 Most Promising Psychedelic Stocks to Buy in February
Via InvestorPlace
6 Largest Psychedelic Stocks Down 3% This Week
Via Talk Markets
Psychedelic Stock Gainers And Losers From February 3, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 2, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 1, 2023
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
Via Investor Brand Network
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Via Benzinga
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
The "Multi-Bagger" Portfolio Update: Week Ending January 27
Via Talk Markets
Largest Psychedelic Stocks +1.2% This Week; Now +16.1% YTD
Via Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Via Investor Brand Network
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Cybin to Host Virtual R&D Day on February 28, 2023
From Cybin Inc.
Via Business Wire
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 23, 2023
Via Benzinga
Largest Psychedelic Stocks +3% This Week; Now +15% YTD
Via Talk Markets
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.